Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- Alogliptin Approval to Be Delayed at Least 2 Years: Takeda
July 6, 2009
- REGULATORY NEWS IN BRIEF
July 6, 2009
- Sandoz's Growth Hormone Approved as Japan's First Biosimilar
July 6, 2009
- JSGM Proposes Free Pricing System for Generics
July 6, 2009
- Korosho Asks MEXT to Cooperate to Increase Use of Generics by National Univ. Hospitals
July 6, 2009
- J&J to Launch Cor-Tyzine for Nasal Allergy
July 6, 2009
- Kyowa Kirin Initiates PII Trial for KW-0761 in Japan
July 6, 2009
- R&D NEWS IN BRIEF
July 6, 2009
- Korosho's Council Recommends Early Development of Plerixafor
July 6, 2009
- NEW PRODUCTS
July 6, 2009
- JSA Proposes Outline of Law on Measures against Stroke
July 6, 2009
- ExAblate 2000 Recommended for Approval for Treatment of Uterine Myoma
July 6, 2009
- GSK Makes Full Entry into Oncology Market with Tykerb
July 6, 2009
- ArBlast's Cultured Corneal Epithelial Cell Sheet Passes CDFS Committee
July 6, 2009
- Otsuka: Mainstay Products Drive Sales up to ¥440.4 Bil.
July 6, 2009
- 4 Med Materials Recommended for Health Insurance Coverage
July 6, 2009
- Bayer Moves Oncology Business Unit to Tokyo
July 6, 2009
- IP Injection of Paclitaxel Approved
July 6, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…